Comparison 12. Hyalgan versus triamcinolone hexacetonide.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain on nominated activity (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 End of treatment (week 4)	1	56	Mean Difference (IV, Fixed, 95% CI)	‐0.20 [‐17.39, 16.99]
1.2 14 to 26 weeks post‐injection	1	20	Mean Difference (IV, Fixed, 95% CI)	‐10.0 [‐31.83, 11.83]
2 Pain at rest (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 End of treatment (week 4)	1	56	Mean Difference (IV, Fixed, 95% CI)	‐0.70 [‐18.17, 16.77]
2.2 14 to 26 weeks post‐injection	1	20	Mean Difference (IV, Fixed, 95% CI)	‐20.40 [‐43.92, 3.12]
3 Pain at night (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 End of treatment (week 4)	1	56	Mean Difference (IV, Fixed, 95% CI)	‐7.10 [‐24.30, 10.10]
3.2 14 to 26 weeks post‐injection	1	20	Mean Difference (IV, Fixed, 95% CI)	‐20.70 [‐37.74, ‐3.66]
4 Safety: total withdrawals overall	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 End of treatment (week 4)	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.18, 2.99]
4.2 14 to 26 weeks post‐injection	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.56, 1.14]
5 Safety: wIthdrawals due to lack efficacy	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 End of treatment (week 4)	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	4.85 [0.24, 97.11]
5.2 14 to 26 week post‐injection	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.49, 1.65]
6 Safety: wIthdrawals due to adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 End of treatment (week 4)	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.06, 14.82]
6.2 14 to 26 weeks post‐injection	1	63	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.23, 2.62]